Overview

Quadratus Lumborum Block for Abdominoplasty

Status:
Completed
Trial end date:
2017-12-13
Target enrollment:
Participant gender:
Summary
Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and sterile sodium chloride in the control group. The aim of study is to investigate the effect of a QL Block on the perioperative pain during postbariatric abdominoplasty.
Phase:
Phase 4
Details
Lead Sponsor:
Vestre Viken Hospital Trust
Treatments:
Ropivacaine